Glatiramer acetate - Evidence for a dual mechanism of action

被引：53

作者：

Blanchette, Francois ^{[1
]}

Neuhaus, Oliver ^{[2
]}

机构：

[1] Teva Pharma SA, F-92936 Paris, France

[2] Kreiskrankenhaus Sigmaringen, Dept Neurol, D-72488 Sigmaringen, Germany

来源：

JOURNAL OF NEUROLOGY | 2008年 / 255卷 / Suppl 1期

关键词：

glatiramer acetate; multiple sclerosis; inflammation; neuroprotection; T-cell;

D O I：

10.1007/s00415-008-1005-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Glatiramer acetate is a disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis. Since its discovery almost four decades ago, and in particular since the observation of its beneficial clinical effects in the late 1980s and early 1990s, numerous data have been generated and contribute pieces of a puzzle to help explain the mechanism of action of glatiramer acetate. Two major themes have emerged, namely (i) the induction of glatiramer acetate-reactive TH2 immunoregulatory cells, and (ii) the stimulation of neurotrophin secretion in the central nervous system that may promote neuronal repair.

引用

页码：26 / 36

页数：11

共 54 条

[41] Short-term brain volume change in relapsing-remitting multiple sclerosis - Effect of glatiramer acetate and implications [J].